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Abstract
Purpose: Acquisition timing and B1 calibration are two key factors that affect the quality and
accuracy of hyperpolarized 13C MRI. The goal of this project was to develop a new approach
using regional bolus tracking to trigger Bloch-Siegert B1 mapping and real-time B1 calibra-
tion based on regional B1 measurements, followed by dynamic imaging of hyperpolarized 13C
metabolites in vivo.
Methods: The proposed approach was implemented on a system which allows real-time data
processing and real-time control on the sequence. Real-time center frequency calibration
upon the bolus arrival was also added. The feasibility of applying the proposed framework
for in vivo hyperpolarized 13C imaging was tested on healthy rats, tumor-bearing mice and a
healthy volunteer on a clinical 3T scanner following hyperpolarized [1-13C]pyruvate injection.
Multichannel receive coils were used in the human study.
Results: Automatic acquisition timing based on either regional bolus peak or bolus ar-
rival was achieved with the proposed framework. Reduced blurring artifacts in real-time
reconstructed images were observed with real-time center frequency calibration. Real-time
computed B1 scaling factors agreed with real-time acquired B1 maps. Flip angle correc-
tion using B1 maps results in a more consistent quantification of metabolic activity (i.e,
pyruvate-to-lactate conversion, kPL). Experiment recordings are provided to demonstrate
the real-time actions during the experiment.
Conclusion: The proposed method was successfully demonstrated on animals and a human
volunteer, and is anticipated to improve the efficient use of the hyperpolarized signal as well
as the accuracy and robustness of hyperpolarized 13C imaging.
Key words: Real-time, Bloch-Siegert, B1 mapping, 13C, Hyperpolarized, MRI,
metabolic imaging, Bolus tracking, Pyruvate
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Introduction
Magnetic resonance imaging with hyperpolarized 13C-labeled compounds prepared via dy-
namic nuclear polarization (1) has been used to non-invasively study metabolic processes in
vivo (2). In this method, the hyperpolarized state of the agent and any metabolic products
will irreversibly decay to thermal equilibrium due to metabolic conversion, RF depletion and
T1 relaxation. Hyperpolarized [1-13C]pyruvate has been widely used to monitor metabolic
pathways (3–12) and its feasiblity for human study has been demonstrated (11,12). The T1s
of hyperpolarized [1-13C]pyruvate and its downstream metabolites (e.g. lactate) at clinical
field strengths are estimated to be 25s to 45s (11, 13) in vivo. In light of the nonrenewable
nature and fast decay of the hyperpolarized magnetization, acquisition timing and transmit
power (B1) calibration are two key factors that affects the quality and accuracy of hyperpo-
larized 13C imaging.
Bolus tracking for triggering the acquisition has been used in clinical MRI for proton MR
angiography (14). Appropriate acquisition timing for hyperpolarized 13C imaging is useful
in several aspects: a) Excitation before the bolus arrival may saturate the nonrecoverable
hyperpolarized signal particularly near the coils conductive elements where the B1 can be
elevated. b) Many variable flip schemes (15–18) that optimize the hyperpolarized MRI sig-
nal sampling require knowledge of the bolus arrival. c) It is more straightforward for kinetic
modeling to start signal sampling after the bolus maximum (19) to eliminate the need to
account for the input function. d) Inconsistent acquisition timing leads to quantification
errors when metabolite to substrate ratios are used as a quantitative metric (19, 20). Cur-
rently, in vivo hyperpoliarized 13C imaging protocols typically start at a certain delay time
after bolus injection. The delay time is determined based on prior knowledge, which can
be unreliable due to the inherent physiological variability of each individual. This is par-
ticularly problematic in human subjects in which 12 s variations in bolus arrival have been
observed (11). This variability can be further exacerbated in tumors where the vascular-
ization and perfusion are highly inconsistent over subjects (21). Recently, a bolus tracking
2
method using a slab FID as tracking signal was demonstrated (19) for automatic acquisition
timing. However, this method didn’t reflect the signal variation within the imaging slab. In
this study, bolus tracking was improved by using the bolus signal from a region of interest
(ROI) on a tracking image rather than from the entire excitation slab.
In the context of hyperpoliarized 13C MRI, B1 calibration is crucial for variable flip angle
schemes (15, 16, 18) and quantification of metabolic activities (22). Due to the virtually
non-existent endogenous 13C signal, 13C B1 calibration is typically performed on external
phantoms, but this approach does not account for the variability of subject loading. Bloch-
Siegert B1 mapping has been applied to hyperpolarized 13C imaging (23, 24) and is advan-
tageous due to its short acquisition time and efficient use of the hyperpolarization signal.
However, real-time power compensation has not yet been accomplished to calibrate the flip
angle during the scan.
This work presents a new approach using regional bolus tracking to trigger Bloch-Siegert
B1 mapping and real-time RF power compensation based on regional B1 measurements fol-
lowed by dynamic imaging of hyperpolarized 13C metabolites. Real-time center frequency
calibration upon bolus arrival was also implemented. Thermally polarized 13C phantom ex-
periments were performed to validate Bloch-Siegert B1 mapping. The feasibility of applying
the proposed framework for in vivo hyperpolarized 13C imaging was demonstrated on healthy
rats, tumor-bearing mice and a healthy volunteer on a clinical 3T scanner. This proposed
method was designed to improve the efficient use of the hyperpolarized signal as well as the
accuracy and the robustness of hyperpolarized 13C imaging.
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Methods
Real-time Hyperpolarized 13C MRI
The proposed scheme is illustrated in Fig. 1. ROIs for both bolus tracking and B1 calibration
are prescribed according to proton anatomical images before starting 13C sequences. The
bolus tracking sequence starts before the hyperpolarized substrate is injected. Real-time
center frequency calibration based on the acquired slab frequency spectrum can be triggered
upon the bolus arrival. When the peak bolus signal in the prescribed ROI is detected,
Bloch-Siegert B1 mapping is triggered and the RF power for all sequences is then calibrated
in real time based on the measured ROI B1. The sequence triggered upon the completion
of B1 calibration for most experiments in this study is alternate pyruvate/lactate dynamic
imaging, which could be replaced by any hyperpolarized 13C sequence for other studies. Our
proposed scheme was implementedon a GE Signa MR 3T scanner (GE Healthcare, Waukesha,
WI) using a commercial software (RTHawk, HeartVista, Los Altos, CA) which allows for
real-time reconstruction of acquired data and feedback control of the pulse sequence. The
software was installed on a workstation (2.4GHz, 16 proccessors, 64 GB RAM) running the
Ubuntu operating system.
The bolus tracking sequence used a singleband spectral-spatial excitation pulse and a single-
shot spiral readout, similar to Fig. 2 but without the Fermi pulse and associated delay. In
these studies, this was used for selective imaging of [1-13C]pyruvate, but could be adapted for
other metabolites (e.g. 13C-urea). The algorithm for tracking the maximum bolus signal was
implemented based on prior works (14,19). The bolus signal is the mean value of a prescribed
ROI on the tracking image. Our bolus tracking acquisition consists of two modules, i.e., noise
calibration and bolus tracking, which can be performed independently. Noise calibration is
used to determine the tracking threshold. If the tracking threshold has been previously
computed, bolus tracking can be performed without running noise calibration. In the noise
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calibration module, the tracking threshold Sthr is determined as Sthr = cthrσ = cthr mnoise√pi
2
,
where σ is the standard deviation of Gaussian noise in the complex image, mnoise is the mean
value of magnitude images of noise and cthr is a scaling factor. 100 calibration scans (TR
= 200 ms) are performed to compute mnoise which is converted to σ (25). Given the noise
distribution of the background in magnitude images follows a Rayleigh distribution (25),
if a probability Pthr that a noise signal is above the tracking threshold is required, the
proportional relationship between Sthr and σ can be derived using the cumulative distribution
function of a Rayleigh distribution. For example, cthr = 3 would result in a Pthr of 0.001%.
In the bolus tracking module, the sequence is resumed automatically if the bolus peak is
not detected. When a cumulative number ncum of signal increases is detected and all these
signals are above the tracking threshold as well as greater than upeak fraction of its previous
signal, the program starts to update the peak value. When the bolus signal is lower than
upeak fraction of the current peak signal, detection of bolus peak will be reported. In our
study, upeak was determined based on estimated hypolarization loss due to T1. For example,
under the assumptions of a T1 of 30s, an excitation flip angle of 5o, no more pyruvate from
the bolus coming into the ROI and neglecting metabolic conversion, the hyperpolarization
loss over a TR of 1s for the bolus tracking sequence would be 1 - cos(5o × pi/180) × exp(-
1/30) = ∼0.04, and the remaining hyperpolarization (∼0.96) was used as upeak. The use of
cumulative increase rather than successive increase as used in the previous work (19) aims
to improve the robustness of the tracking algorithm to motion and injection with unstable
rates. For some experiments, during the time that bolus signal was below the current signal
peak but above upeak threshold, a short repetition time was used to shorten the time interval
between actual bolus peak and detected bolus peak.
The Bloch-Siegert B1 mapping sequence (23, 24, 26) (Fig. 2) shared the similar excitation
and readout as bolus tracking, using a singleband spectral-spatial excitation pulse and a
single-shot spiral readout, whereas an off-resonance Fermi pulse (KBS = 6.76rad/G2 ) was
inserted in between. The phase difference between two Bloch-Siegert B1 mapping sequences
with opposite ωRF was used to calculate B1. Taking the phase difference removes receiver
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phase and minimizes the influence of B0 off-resonance frequency (26). Parameters used in
this study were designed to measure a maximum B1 of 0.48G. The two phase maps were
masked based on corresponding magnitude images in order to eliminate noisy phases due to
low signal. The threshold is determined as SB1 = cB1σ, where cB1 is a scaling factor and
noise standard deviation σ was obtained from the bolus tracking sequence. The ratio of
the desired B1 to the measured ROI B1 was passed to all sequences as a scaling factor to
calibrate transmit power in real time.
The center frequency calibration sequence consists of a sinc excitation pulse with slab selec-
tion gradient and a 102 ms readout with a 5kHz bandwidth. The acquired spectrum is used
to calibrate center frequency for all sequences in real time. Alternate pyruvate and lactate
dynamic imaging shared the same excitation and readout as bolus tracking, using a single-
band spectral-spatial excitation pulse and a single-shot spiral readout, but with alternating
excitation frequencies and different flip angles to image pyruvate and lactate.
All methods described are available through the HeartVista research collaboration portal
(https://www.heartvista.com/git/shuyu/hv_research_shuyu).
Phantom and Animal Experiments
Validations of the Bloch-Siegert B1 mapping sequence were performed on a 13C/1H birdcage
coil as well as on a 13C figure-8 transceiver coil. For experiments using the 13C/1H birdcage
coil, a cylindrical ethylene glycol phantom with a base of 3.6cm diameter was used. Axial 13C
B1 maps at four transmit powers (50%, 75%, 100% and 150% of the calibrated power) were
acquired (FA 90o, slice thickness 10mm, Fermi pulse duration TRF 12ms, frequency offset ωRF
±4.5kHz, FOV 10cm, in-plane resolution 2.5 × 2.5mm, TR 2s, NEX 100). For experiments
using the 13C figure-8 transceiver coil, a cup (cross-section diameter from 5.5 to 7.5cm, height
7.5cm) filled with oil was placed on top of the coil. An axial 13C magnitude map with a
nominal 180o excitation (FA 180o, slice thickness 100mm, FOV 20cm, in-plane resolution 5
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× 5mm, TR 1s, NEX 100) and its corresponding B1 map (FA 60o, slice thickness 100mm,
Fermi pulse duration TRF 8ms, frequency offset ωRF ±3kHz, FOV 20cm, in-plane resolution
5 × 5mm, TR 1s and NEX 200) were acquired. A 2D phase unwrapping algorithm (27)
based on minimum spanning tree was implemented to correct phase images of B1 mapping
off line.
Hyperpolarized 13C animal experiments were performed to test our proposed scheme using
normal Sprague-Dawley rats and transgenic adenocarcinoma of mouse prostate (TRAMP)
mice with 13C/1H birdcage coils (8cm diameter for rats, 5cm diameter for mice). Two experi-
ments were also performed on a rat with a 13C figure-8 transceiver coil. A total of six rats and
two TRAMP mice were used to test the proposed scheme.All animal studies were conducted
under protocols approved by the University of California San Francisco Institutional Animal
Care and Use Committee (IACUC). Both rats and mice were anesthetized with isoflurane
(1-2%) and placed in a supine position on a heated pad throughout the duration of the
experiments. [1-13C]pyruvic acid (Sigma Aldrich, St. Louis, MO) mixed with 15mM trityl
radical (GE Healthcare, Waukesha, WI) and 1.5mM Gd-DOTA (Guerbet, Roissy, France)
was polarized in a HyperSense dissolution DNP system (Oxford Instruments, Abingdon, UK)
at 1.35K and 3.35T for ∼1h. A 4.5mL volume of 80mM NaOH and 40mM Tris buffer was
used as dissolution media, resulting in a 80mM [1-13C]pyruvate solution, with final pH of
6-8. The hyperpolarized [1-13C]pyruvate was injected into the animal via tail vein catheters,
∼2.6mL for each rat and ∼350µL for the mouse. Each animal received two injections.
All animal experiments were performed using the proposed scheme (Fig. 1). 13C sequence
parameters for animal experiments are shown in Table 1. Some experiments were performed
with real-time center frequency calibration. The desired B1 of the Fermi pulse in B1 mapping
sequence for all experiments was always set to 0.3G (344% of B1 required for a 90o excitation
of the spectral-spatial pulse used in this study). Using the measured transmit B1 maps, all
in vivo results were compensated for spatial B1 variations and flip angles between sequences.
RF power measurements are shown as relative B1 maps which is the measured B1 normalized
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by the desired B1. For some experiments, data from alternate pyruvate and lactate dynamic
imaging was used to quantify pyruvate-to-lactate conversion rate (kPL) based on a two-site
exchange model (28) using non-linear least-squares fitting.
For rat experiments using the 13C/1H birdcage coil, an anatomical localizer was acquired
using proton 3D bSSFP sequence (FOV 16 × 8 × 4.8cm, Matrix size 256 × 256 × 76). A
total number of five injections were performed on three rats using the proposed scheme with
different combinations of injection times (8s, 12s) and transmit gains (100%, 120% of pre-
scan power calibration). Real-time center frequency calibration were not performed in these
studies. A 13C urea phantom was used for frequency and pre-scan power calibrations. 13C
images were acquired on the axial kidney plane. ROIs for bolus tracking and B1 calibration
were both placed on the left kidney.
For rat experiments using the 13C transceiver coil, an anatomical localizer was acquired using
proton T2-weighted fast spin echo sequence (FOV 6 × 6cm, Matrix size 256 × 256) with
the scanner body coil. The rat was positioned in a way that right kidney was about 1 cm
further than left kidney from the bottom 13C transceiver coil. This set up was designed to
produce a distinct B1 variation between two kidneys. Two injections were performed using
the proposed scheme with the same parameters but with different tracking/B1 calibrating
ROIs, one on right kidney and the other on left kidney. A 13C urea phantom embedded on
the coil was used for pre-scan frequency calibration. Real-time center frequency calibration
was performed at the bolus arrival. 13C images were acquired on the axial kidney planes with
an injection time of 10s and transmit gain set based on pre-scan with the 13C-urea phantom.
For the TRAMP experiment, an anatomical localizer was acquired using proton T2-weighted
fast spin echo sequence (FOV 6 × 6cm, Matrix size 256 × 256). Real-time center frequency
calibration was performed at the bolus arrival. 13C images were acquired on the axial tumor
plane with a injection time of 12s and transmit gain the same as the calibrated power in
pre-scan. A 13C urea phantom was used for pre-scan frequency and power calibration. ROIs
for bolus tracking and B1 calibration were both in the tumor.
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Volunteer Study
One human study was performed to test the proposed scheme (Fig. 1). A healthy volunteer
was recruited with institutional review board approval and provided with written informed
consent for participation in the study. The volunteer was a 37-year-old male. An Investi-
gational New Drug approval was obtained from the U.S. Food and Drug Administration for
generating the agent and implementing the clinical protocol. 1.47g of Good Manufacturing
Practices (GMP) [1-13C]pyruvate (Sigma Aldrich, St. Louis, MO) mixed with 15mM elec-
tron paramagnetic agent (EPA) (AH111501, GE Healthcare, Oslo, Norway) was polarized
using a 5T SPINlab polarizer (General Electric, Niskayuna, NY) for 3h before being rapidly
dissolved with 130oC water and forced through a filter that removed EPA. The solution
was then collected in a receiver vessel and neutralized with NaOH and Tris buffer. The
receive assembly that accommodates quality-control processes provided rapid measurements
of pH, pyruvate and EPA concentrations, polarization, and temperature. In parallel, the
hyperpolarized solution was pulled into a syringe (Medrad Inc, Warrendale, PA) through a
0.5µm sterile filter (ZenPure, Manassas, VA) and transported into the scanner for injection.
The integrity of this filter was tested in agreement with manufacturer specifications prior to
injection. A 0.43mL/kg dose of ∼250mM pyruvate was injected at a rate of 5mL/s via an
intra-venous catheter placed in the antecubital vein, followed by a 20mL saline flush.
In this study, 13C axial brain images were acquired with in-house built birdcage transmit coil
and 32-channel receive array (29). Different from animal experiments, excitation pulses for
bolus tracking, B1 mapping and metabolic-specific dynamic imaging were replaced with a dif-
ferent singleband spectral-spatial RF pulse (130Hz FWHM passband, 870Hz stopband) (30).
Single-slice real-time B1 calibration was triggered right after real-time center frequency cali-
bration rather than on bolus peak. The ROI for both bolus tracking and B1 calibration was
on the brain tissue near the superior sagittal sinus. Following B1 calibration, multi-slice 2D
acquisitions were performed to cover the entire brain, and [1-13C ]pyruvate, [1-13C ]lactate
and [1-13C ]bicarbonate signals were acquired alternately. A 13C urea phantom embedded
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on the coil was used for pre-scan frequency calibration. Pre-scan power calibration was per-
formed on a 13C ethylene glycol head phantom. Proton anatomical reference was acquired
with body coil built in the scanner, using 3D T1-weighted spoiled gradient echo with FOV
26.6x26.6x16cm3, matrix size 256x256x160. 13C sequence parameters for this study are pre-
sented in Table 2.
For the online reconstruction, multichannel k-space data were combined using sum of squares.
In the offline processing, coil combination was performed by using pyruvate signals as coil
sensivitiy maps (31).
Results
Axial thermal 13C B1 maps of the 13C/1H birdcarge coil at 50%, 75%, 100% and 150% of
the calibrated transmit power are shown in Fig. 3a. The mean B1 value of the phantom
region versus the relative transmit power is plotted (Fig. 3b) to demonstrate the quadratic
relationship between Bloch-Siegert phase difference and transmit power. A comparison be-
tween the magnitude image of nominal 180o excitation and its corresponding B1 map of a
thermal 13C phantom on the 13C transceiver coil is shown in Fig. 3c and Fig. 3d. The B1
value along the dark band in Fig. 3c and its corresponding theoretical excitation flip angle
(0.3 G) is plotted in Fig. 3e, demonstrating the accuracy of Bloch-Siegert B1 mapping.
Results of a representative hyperpolarized [1-13C]pyruvate experiment using the proposed
scheme to image the kidneys of a healthy rat with 13C/1H birdcage coil are shown in Fig.
4. Real-time center frequency calibration was not performed in this study. Fig. 4d displays
every other timeframe of the real-time reconstructed data where magnitude images are nor-
malized by the peak value of the corresponding metabolic series. The full set of images can
be found in Sup. Fig. S1. The acquired B1 map (Fig. 4b) was homogenous, as expected for
this coil. The initial transmit power was purposely set to 120% of the power calibrated on a
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thermal 13C phantom and resulted in a nominal B1 scaling factor of 0.83 (1/1.2), which was
in reasonable agreement with the real-time computed B1 scaling factor of ∼0.87. Normalized
pyruvate signal curves combining the data of bolus tracking and pyruvate/lactate dynamic
imaging are shown in Fig. 4c for different ROIs. These pyruvate signal curves demonstrate
that the ROI (left kidney) bolus peak was successfully detected, and acquisition timing would
be different if the tracking ROI was on the major vessels.
Results of a hyperpolarized [1-13C]pyruvate experiment using the proposed scheme to image
the tumor of a TRAMP mouse with 13C/1H birdcage coil is shown in Fig. 5. Fig. 5e
displays every other timeframe of the real-time reconstructed data where magnitude images
are normalized by the peak value of the corresponding metabolic series. The full set of images
can be found in Sup. Fig. S2. The frequency spectrum (Fig. 5d) acquired from the imaging
slab at the bolus arrival shows that the measured pyruvate frequency was 20Hz downfield
from the frequency calibrated based on a thermal 13C phantom. Bolus tracking images right
before and after real-time center frequency calibration in Fig. 5e demonstrate that real-time
center frequency calibration reduced blurring caused by off resonance reconstruction in real-
time reconstructed images. Fig. 5b depicts the normalized B1 map which is homogenous as
expected for the coil. The real-time B1 scaling factor (Fig. 5b) was 1.05, indicating a 5%
difference from the power calibrated on a thermal 13C phantom. Tumor kPL (Fig. 5c) fitted
using pyruvate and lactate signals was ∼ 0.09 s−1, agreeing with prior works (32) which
showed a kPL range of 0.03 to 0.08 s−1 for high grade TRAMP tumor.
Results of two hyperpolarized [1-13C]pyruvate experiments using the proposed scheme to
image the kidneys of healthy rats with one-sided 13C surface transceiver coil are shown in
Fig. 6. Two experiments were performed with the same parameters but with the different
tracking/calibrating ROIs, one on the right and the other on the left kidney, where the left
kidney was closer to the coil. B1 maps (Fig. 6b) acquired in two experiments are consistent
and show that the left kidney experienced a 40% higher B1 than the right kidney did. This
agreed with the real-time B1 scaling factors, 1.49 and 1.07 for the tracking experiments on
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the left and right kidney, respectively. kPL maps fitted with and without flip angle correction
for the two experiments are shown in Fig. 6c, where kPL values of right kidney, left kidney
and intestine are labeled. Root mean squared errors of kPL values in the three labeled ROIs
between two experiments are 0.0033 with flip angle correction and 0.0045 without flip angle
correction, demonstrating that using acquired B1 maps to correct flip angle results in more
consistent kPL estimations.
Results of the hyperpolarized [1-13C]pyruvate human experiment using the proposed scheme
to image the brain are shown in Fig. 7 and Fig. 8. The polarization of the injected dose,
back-calculated to the time of dissolution, was 41.9%. The ROI for both bolus tracking and
B1 calibration was on the brain tissue near the superior sagittal sinus of slice 5. The frequency
spectrum (Fig. 7c) acquired from slice 5 upon the bolus arrival shows that the measured
pyruvate frequency was the same as the frequency calibrated in pre-scan. Fig. 7b depicts
the normalized B1 map which is homogenous as expected for the birdcage transmit coil. The
real-time B1 scaling factor (Fig. 7b) was ∼1.04, 4% difference from the power calibrated in
pre-scan. Pyruvate, lactate and bicarbonate sum-over-time images are displayed in Fig. 8,
where maximum SNRs for pyruvate, lactate and bicarbonate are 627, 60 and 20, respectively.
Dynamic images can be found in Sup. Fig. S3.
Experiment recordings are provided on YouTube (see links in the figure) to demonstrate
real-time actions during the experiments.
Discussion
As discussed in the Introduction section, automatic acquisition timing via bolus tracking
improves efficient use of hyperpolarization as well as consistency and accuracy of hyperpo-
larized 13C imaging. Furthermore, accurate timing is critical for some optimal variable flip
angle schemes and metabolic quantification (15–18). The implementation of regional bo-
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lus tracking in this work improves the flexibility and accuracy of acquisition timing, and it
would be especially useful for imaging tissue with low perfusion rate where injected metabo-
lites would arrive at the target region later relative to major vessels or other tissues. The
resolution of the bolus tracking image should be chosen as coarse as possible to improve
image SNR but fine enough to separate the desired tracking region (e.g. major vessels from
other tissues). An alternative approach is to use 2D spatially selective excitation pulses,
but this approach is less robust to signals from off-resonance metabolites. In this study,
bolus tracking triggered its following sequences either upon bolus arrival or following peak
detection. This could easily be modified to use other schemes, such as starting metabolic
imaging during the bolus or adding an additional delay from the peak. Manually triggering
sequences during bolus tracking is also allowed in the designed framework and is useful if
the automatic tracking algorithm fails. The bolus tracking used a flip angle of 5o and a TR
of 1 s. Assuming an injection time of 10s, the expected total hyperpolarized signal loss due
to bolus tracking RF pulses would be less than 2%.
The naturally low-abundance 13C signal requires real-time B1 mapping for accurate in vivo
measurements of RF power in hyperpolarized 13C imaging. The acquired B1 map is useful for
flip angle correction of images and is crucial for quantification of metabolism (e.g. kPL (22))
as demonstrated in in vivo results (Fig. 6). Real-time B1 calibration could achieve accurate
flip angle during the scan, which is critical for variable flip angle schemes (15–18) and large
flip angle pulses (33), and avoiding unnecessary use of hyperpolarization. The upper limit
of the B1 measurement depends on the KBS value of the Bloch-Siegert pulse while the lower
limit depends on the SNR. 2D phase unwrapping could be implemented in real time to
extend the upper limit of B1 measurement. Real-time masking of the acquired B1 map
based on signal intensity made the real-time B1 calibration robust when the B1 calibration
ROI contained regions with low hyperpolarized signal. The two TRs required for the B1
mapping sequence used a pyruvate flip angle of 10o, using only 3% of the hyperpolarization
magnetization.
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Center frequency calibration is crucial for metabolite specific imaging. For singleband
spetral-spatial pulses, frequency calibration errors will reduce the flip angle and may also
excite undesired resonances. For spiral or echo-planar imaging (EPI) readouts, frequency
calibration errors will lead to off-resonance blurring and shift artifacts. Both of these factors
can undermine the accuracy of Bloch-Siegert B1 mapping and quantification of metabolism.
Using a thermal 13C phantom, which must be placed external to the subject, center frequency
calibration doesn’t capture B0 within the subject. Although B0 maps can be obtained via
proton imaging, in vivo shimming could still be challenging, particularly in the presence of
motion. In this study, real-time center frequency was triggered upon bolus arrival, which
improved the quality of all the following real-time reconstructed images (Fig. 5e). The
102ms readout duration of the center frequency measurement sequence resulted in a ∼10Hz
frequency resolution which could be improved with a longer readout duration. A 3o flip angle
cost less than 0.2% hyperpolarization.
The transition time between acquisitions is mainly attributed to real-time image recon-
struction and loading sequence waveforms. For animal experiments using single-channel
acquisition, the transition times of a bolus tracking acquisition, real-time center frequency
calibration, real-time B1 calibration and their following sequences were about 60ms, 60ms
and 400ms, respectively. For the human experiment using 32-channel acquisition, a longer
transition time (∼800ms) was observed for real-time B1 calibration, whereas transition times
for bolus tracking acquisition and real-time center frequency calibration remained similar.
The longer transition time found in B1 calibration could be caused by its more complicated
reconstruction compared to frequency calibration, and its shorter TR compared to a bolus
tracking acquisition which typically used a TR of 1s and allowed real-time reconstruction to
be completed during the dead time of a TR.
A 13C-pyruvate and 13C-urea co-polarized injection (34) would benefit substantially from
the proposed methods. 13C-urea could be used to perform bolus tracking, real-time center
frequency and B1 calibration. This strategy would fully reserve hyperpolarized signal of
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pyruvate (19) and provide higher SNR for B1 mapping by using a larger flip angle. Car-
diac and respiratory motion could detrimentally affect bolus tracking and Bloch-Siegert B1
mapping. Cardiac gating could be used (23). In terms of respiratory motion, breathholding
is often used in clinical studies. Respiratory gating is not suitable for bolus tracking due
to large potential delays but can be applied to perform B1 mapping at the end of exhala-
tion (23), in which case, a short TR (200ms) as used in this study is recommended. A more
challenging but robust approach to handle motion is to perform real-time image registration.
To extend the proposed scheme for volumetric calibration, real-time center frequency and
B1 calibration can be integrated with a multislice imaging framework (23). More than one
ROI for tracking or B1 calibration could be useful when B1 (e.g. Fig. 6b) or acquisition
timing (e.g. Fig. 4c) shows variation within the imaging subject.
Conclusion
This work demonstrated an approach that integrates automatic acquisition timing using the
regional bolus signal with real-time center frequency calibration, Bloch-Siegert B1 mapping
and real-time RF power compensation based on regional B1 measurements as well as dynamic
hyperpolarized 13C imaging. This scheme allows for timing the acquisition based on bolus in-
formation of a local region within the imaging plane. Acquiring in vivo B1 maps, performing
real-time center frequency calibration and B1 calibration, ensures accurate center frequency
and flip angles which are used in the following hyperpolarized 13C sequences. The proposed
scheme was successfully demonstrated for in vivo hyperpolarized [1-13C]pyruvate imaging on
a clinical 3T scanner. Future work will focus on incoporating pyruvate-urea co-polarized in-
jections, volumetric calibration and motion-compensation methods into the proposed scheme
to improve efficiency, accuracy, and robustness of hyperpolarized 13C studies.
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1 Overview of the proposed scheme. Bolus tracking starts before the bolus
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Figure 1: Overview of the proposed scheme. Bolus tracking starts before the bolus injection.
Real-time center frequency calibration (‘CF Cal’) based on a slab FID is triggered upon
ROI bolus arrival, while Bloch-Siegert B1 mapping and real-time ROI B1 calibration (‘B1
Cal’) are triggered at the ROI bolus peak. The sequence triggered after B1 calibration for
most experiments in this study is alternate pyruvate/lactate dynamic imaging, and could be
replaced by any hyperpolarized 13C sequence for other studies.
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Figure 2: Metabolite-specific imaging sequence used in this study, where all instances in-
cluded a singleband spectral-spatial excitation pulse (passband 120 Hz, stopband 600 Hz)
and a single-shot spiral readout. The sequence shown also includes an off-resonance Fermi
pulse (TRF = 12 ms, ωRF = ±4.5 kHz) for Bloch-Siegert B1 mapping, while bolus tracking
and pyruvate/lactate dynamic imaging also used this sequence but without Fermi pulse and
its associated delay. Other key parameters for bolus tracking were FA 5o (pyruvate), TR 1s;
and for Bloch-Siegert B1 mapping were FA 10o (pyruvate), TR 200ms.
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Figure 3: Validation of Bloch-Siegert B1 mapping on the 13C/1H birdcage coil using a cylin-
drical ethylene glycol phantom (a-b) and on the 13C figure-8 transceiver coil using a cup
filled with oil (c-e). For the latter experiment, the oil cup was placed on the top of the 13C
coil. In both experiments, the desired B1 of the Bloch-Siegert pulse was 0.3G, at which the
excitation pulse would produce the theoretically accurate flip angle. (a) Axial 13C B1 maps
of birdcarge coil with 50%, 75%, 100% and 150% relative to the calibrated transmit power
in pre-scan. (b) A plot of Bloch-Siegert phase difference versus relative transmit power.
Each data point corresponds to the mean value of the phantom area of each B1 image in
(a). The data point at the relative power of zero is estimated to be zero. The quadratic
curve is computed by a least-squares fitting. (c) Axial 13C image of transceiver coil with a
nominal 180o flip angle. The dark band in the image corresponds to a 180o signal null. (d)
Corresponding axial B1 map of (c), where the dark band corresponds to ∼0.3 G as expected.
(e) A plot of B1 value across the dark band and corresponding flip angles calculated based
on the B1 value.
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Figure 4: Results of a hyperpolarized [1-13C]pyruvate study in a normal rat using the pro-
posed method (Fig. 1) with a birdcage coil. Real-time center frequency calibration was not
performed in this study. The ROI for both bolus tracking and B1 calibration was on the left
kidney. Injection time was 8 s and initial power was purposely set to 120% of the calibrated
power in pre-scan. Sequence parameters are presented in Table 1. (a) Proton localizer. (b)
Normalized 13C B1 map. Real-time B1 scaling factor (∼0.87) matched up with the initial
transmit power (120%). (c) Normalized pyruvate signal curves in different ROIs. The ROI
(left kidney) bolus peak was successfully detected. (d) 13C results displayed in the order of
time. Every other timeframe is shown. The full set of images can be found in Sup. Fig. S1.
Experiment recording: https://youtu.be/CN3mIrzmBT8.
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Figure 5: Results of a hyperpolarized [1-13C]pyruvate study in a TRAMP mouse using the
proposed method (Fig. 1) with a birdcage coil. The ROI for both bolus tracking and B1
calibration was the tumor. Injection time was 12 s and initial power was the same as the
calibrated power in pre-scan. Sequence parameters are presented in Table 1. (a) Proton
localizer. (b) Normalized 13C B1 map. (c) Pyruvate-to-lactate conversion rate(kPL) map
with corrected flip angle. (d) Acquired frequency spectrum for center frequency calibration.
“Center frequency” is abbreviated as “cf” in the figure. (e) 13C results displayed in the
order of time. Every other timeframe is shown. The full set of images can be found in
Sup. Fig. S2. Bolus tracking images before and after real-time center frequency calibration
demonstrate that real-time center frequency calibration reduced off-resonance artifacts in
real-time reconstructed images. Experiment recording: https://youtu.be/ViTDb3PzK3U.
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Figure 6: Results of two hyperpolarized [1-13C]pyruvate studies in a normal rat using the
proposed method (Fig. 1) with a 13C surface transceiver coil. The two experiments were
performed with the same parameters except for different tracking/calibrating ROIs: exper-
iment #1 on right kidney and #2 was on left kidney, where the left kidney is closer to the
coil. Injection time was 10 s and initial power was the same as the calibrated power in pre-
scan. Sequence parameters are presented in Table 1. (a) Proton localizer. (b) Normalized
13C B1 maps. B1 maps acquired in two experiments are consistent. (c) Estimated kPL with
and without flip angle correction based on measured B1 map. kPL values for left kidney,
right kidney and intestine are labeled in the maps. Using acquired B1 maps to correct flip
angle results in more consistent kPL estimations of those ROIs between the two experiments,
demonstrating the importance of flip angle correction for kPL measurements. Experiment
recordings: https://youtu.be/Mu3NW7Kog9M, https://youtu.be/fL5gVkPDw2o.
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Figure 7: Results of hyperpolarized [1-13C]pyruvate studies on a healthy human volunteer
using the proposed method (Fig. 1) with in-house built birdcage transmit coil and 32-channel
receive array. In this study, single-slice real-time B1 calibration was triggered right after real-
time center frequency calibration. The ROI for both bolus tracking and B1 calibration was
on the brain tissue near the superior sagittal sinus of slice 5 (see Fig. 8 for slice 1-8).
A multi-slice 2D acquisition was used for pyruvate/lactate/bicarbonate dynamic imaging.
Initial power was the same as the calibrated power in pre-scan. Sequence parameters are
presented in Table 2. (a) Proton image of slice 5. (b) Normalized 13C B1 maps. (c) Acquired
frequency spectrum for center frequency calibration. (d) 13C results of slice 5 displayed in
the order of time. Multi-slice dynamic images can be found in Sup. Fig. S3. Sum-over-time
images can be found in Fig. 8. Experiment recordings: https://youtu.be/Oq36Z7ayQ0g.
34
pyruvate
lactate
bicarbonate
anatomical
slice 1 slice 2 slice 3 slice 4 slice 5 slice 6 slice 7 slice 8
Figure 8: Sum of first twenty time points of multi-slice pyruvate/lactate/bicarbonate dy-
namic images as described in Fig. 7 and Sup. Fig. S3. Anatomical images are provided
as coarse anatomical landmarks. Maximum SNRs of sum-over-time images for pyruvate,
lactate and bicarbonate are 600, 58 and 19, respectively.
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Sequence Parameters Rat/Birdcage TRAMP Rat/Surface
Bolus Tracking
Slice thickness (mm) 10 20 10
Resolution (mm2) 2.5 × 2.5 2.5 × 2.5 2.94 × 2.94
Shared Parameters
FOV 10cm, FA 5o, TR 1s/0.5s before/after
bolus peak, upeak 0.95, cthr 6, ncum 3
B1 Mapping
Slice thickness (mm) 10 20 10
Resolution (mm2) 2.5 × 2.5 2.5 × 2.5 2.94 × 2.94
Shared Parameters
FOV 10cm, FA 10o, TR 200ms, cB1 3,
desired B1 0.3G
Pyruvate/Lactate
Dynamic Imaging
FOV (cm) 10 8 10
Slice thickness (mm) 10 20 10
Resolution (mm2) 2.5 × 2.5 2.86 × 2.86 2.94 × 2.94
Shared Parameters FApyr 10o, FAlac 40o , Temporal resolution 2s
Frequency
Calibration
Slice thickness (mm) NA 20 10
Shared Parameters NA FA 3o, TR 150ms
Table 1: 13C sequence parameters for animal experiments shown in Fig. 4 (‘Rat/Birdcage’),
Fig. 5 (‘TRAMP’) and Fig. 6 (‘Rat/Surface’).
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Sequence Parameters
Bolus Tracking
FA 5o, Slice thickness 30mm, Resolution 1.5 × 1.5 cm2,
FOV 39cm, TR 1s, cthr 4
B1 Mapping
FA 10o, Slice thickness 30mm, Resolution 1.5 × 1.5 cm2,
FOV 39cm, TR 200ms, cB1 2, desired B1 0.3G
Multi-slice Pyruvate/
Lactate/Bicarbonate
Dynamic Imaging
FApyr 20o, FAlac 30o, FAbicarb 30o, Slice thickness 20mm,
NSlice 8, FOV 39cm, Resolution 1.5 × 1.5 cm2, TR 125ms,
Temporal resolution 3s
Frequency Calibration FA 3o, Slice thickness 20mm, TR 150ms
Table 2: 13C sequence parameters for the human study shown in Fig. 7 and Fig. 8
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Supporting Figure S1: Results of bolus tracking and pyruvate/lactate dy-
namic imaging of the experiment described in Fig. 4. Fig. 4 shows every
other 13C image in this figure.
2
Supporting Figure S2: Results of bolus tracking and pyruvate/lactate dy-
namic imaging of the experiment described in Fig. 5. Fig. 5 shows every
other 13C image in this figure.
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Supporting Figure S3: The first twenty time points of multi-slice dynamic
images for the hyperpolarized [1-13C]pyruvate human study as described in
Fig. 7.
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